Pre-made Certolizumab biosimilar ( Fab, anti-TNFA therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-100
Anti-TNFA therapeutic antibody (Pre-made Certolizumab biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-��) and is manufactured by UCB.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFA therapeutic antibody (Pre-made Certolizumab biosimilar,Fab)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||5wuv:HL/5wux:HL:AB:CD|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis|
|Conditions Active||Interstitial cystitis;Juvenile rheumatoid arthritis|
|Conditions Discontinued||Cognition disorders|